- Home
- ACET vs SST Comparison
ACET vs SST Comparison
Compare ACET & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACET | SST |
|---|---|---|
| Founded | 1947 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.5M | 67.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACET | SST |
|---|---|---|
| Price | $0.50 | $4.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 2.1M | 30.1K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $289,784,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.45 | $2.90 |
| 52 Week High | $1.11 | $15.00 |
Technical Indicators
Market Signals| Indicator | ACET | SST |
|---|---|---|
| Relative Strength Index (RSI) | 33.21 | 46.04 |
| Support Level | $0.50 | $4.05 |
| Resistance Level | $0.59 | $5.00 |
| Average True Range (ATR) | 0.05 | 0.44 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 2.19 | 45.34 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.